Reposted by Abdullah Abdelaziz
Our new study is out today in @jamanetworkopen.com!
We looked at trends in biologic drug prices after biosimilar competition.
Key takeaways: savings from biosimilars are substantial, but take longer to accrue than commonly seen with generic small molecules.
1/
jamanetwork.com/journals/jam...
jamanetwork.com
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market
This cohort study evaluates the associations of biosimilar entry to the market with the prices of originator biologics under Medicare Part B reimbursement.